Blog Img
Back to blogs

BioNTech Recognises Phaidon International as Key Support Partner for Covid-19 Vaccine

London, UK - 19th January 2021: Phaidon International is honoured to be recognised for its part in BioNTech's journey towards a successful vaccine against Covid-19.

The German-based biotechnology company who was the first to bring a successful vaccine against Covid-19 to market, acknowledges Phaidon International as a key partner in making this historic achievement possible.

Ugur Sahin, CEO and Co-founder of BioNTech, comments: "Despite the damage caused by the virus, I have been inspired each day by the spirit of collaboration and scientific discovery. It is one of the greatest honors of my life to be involved in this effort and to play a role in helping the world regain a sense of normality. I would like to thank each and every person that helped make this a reality."

Phaidon International's recruitment brands specialised in life sciences (EPM Scientific) and end-to-end supply chain (DSJ Global) have been working with BioNTech for a number of years and were pleased to be part of their journey in developing a vaccine.

Harry Youtan, CEO of Phaidon International says: "Often we spend time focusing on the day to day tasks, but on this occasion more than perhaps others, everyone in our team is extraordinarily proud that we are helping, in our own way, to overcome one of the greatest challenges in recent times.โ€‹"

To see the full list of BioNTech partners, click here.

โ€‹

About Phaidon International

Phaidon International is the parent company of five leading specialist recruitment brands. With an integrated network covering the whole globe, our consultants identify hard to find, business-critical talent from a local, regional, and global perspective.